SCHEMBL21130083

SCHEMBL21130083

C=C[C@@]12C[C@@H]1[C@@H](n1ccc3c(C)ncnc31)[C@@H]1OC(C)(C)O[C@@H]12

nearest known ligand 0.37

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 20/20 0.37
▸ WDR77 Q9BQA1 20/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27188770 1.00 PRMT5 (0.37) PRMT5WDR77
SCHEMBL22521454 0.89 PRMT5 (0.42) PRMT5WDR77
SCHEMBL29522691 0.89 PRMT5 (0.42) PRMT5WDR77
SCHEMBL29565934 0.89 PRMT5 (0.34) PRMT5WDR77
SCHEMBL23429787 0.89 PRMT5 (0.34) PRMT5WDR77
SCHEMBL23430012 0.89 PRMT5 (0.42) PRMT5WDR77
SCHEMBL22521404 0.89 PRMT5 (0.34) PRMT5WDR77
SCHEMBL21061719 0.89 PRMT5 (0.42) PRMT5WDR77
SCHEMBL21061526 0.89 PRMT5 (0.34) PRMT5WDR77
SCHEMBL27188768 0.89 PRMT5 (0.34) PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11952380-B2 Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors LUPIN LIMITED (IN) 2024-04-09 — — US disclosed
US-11459330-B2 Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors LUPIN LIMITED (IN) 2022-10-04 — — US disclosed
US-20220267339-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS LUPIN LIMITED (IN) 2022-08-25 — — US disclosed
EP-3724190-B1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS LUPIN LTD (IN) 2022-07-06 — — EP disclosed
US-20210163486-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS LUPIN LIMITED (IN) 2021-06-03 — — US disclosed
WO-2019116302-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS LUPIN LIMITED (IN) 2019-06-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11459330-B2 Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors PRMT5, PRMT1, PRMT3 PRMT5 1/4885WDR77 123/4885
US-20210163486-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 PRMT5 1/4885WDR77 123/4885
US-20220267339-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 PRMT5 1/4885WDR77 123/4885
US-11952380-B2 Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors PRMT5, PRMT1, PRMT3 PRMT5 1/4885WDR77 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback